Ultimovacs ASA (ULTIO.OL)
| Previous close | 74.90 |
| Open | 77.80 |
| Bid | 76.60 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 77.80 - 77.80 |
| 52-week range | 77.80 - 77.80 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Ultimovacs ASA: First quarter 2022 result presentation
Oslo, 12 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today. The presentation by the company's management team can be followed as a live webcast at 13:00 CET and will be made available on the website. It will be possible to post questions during the presentation through the webcast. Highlights for the first quarter of 2022: On 22 April 2022, Ultimovacs received a Notice of Allowance
- Globe Newswire
Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 yearsMeasurable UV1-specific immune response in 91% of patients when combined with checkpoint inhibitor, as compared to 82% and 67% without checkpoint inhibitorImmune responses induced more rapidly when UV1 was combined with a checkpoint inhibitorDevelopment of UV1-specific immune responses associated with longer survival time Oslo, 10 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULT
- Globe Newswire
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation Oslo, 5 May 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its first quarter 2022 results on Thursday 12 May 2022. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 13:00 CET on Thursday 12 May 2022. The webcast presentation will be available on the Ultimovacs websit
